Literature DB >> 23866946

Expression of Wnt and TGF-β pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness.

Helka Parviainen1, Anja Schrade, Sanne Kiiveri, Renata Prunskaite-Hyyryläinen, Caj Haglund, Seppo Vainio, David B Wilson, Johanna Arola, Markku Heikinheimo.   

Abstract

Factors controlling benign and malignant adrenocortical tumorigenesis are largely unknown, but several mouse models suggest an important role for inhibin-alpha (INHA). To show that findings in the mouse are relevant to human tumors and clinical outcome, we investigated the expression of signaling proteins and transcription factors involved in the regulation of INHA in human tumor samples⋅ Thirty-one adrenocortical tumor samples, including 13 adrenocortical carcinomas (ACCs), were categorized according to Weiss score, hormonal profile, and patient survival data and analyzed using immunohistochemistry and RT-PCR. Expression of the TGF-β signaling mediator SMAD3 varied inversely with Weiss score, so that SMAD3 expression was lowest in the most malignant tumors. By contrast, SMAD2 expression was upregulated in most malignant tumors. Wnt pathway co-receptors LRP5 and LRP6 were predominantly expressed in benign adrenocortical tumors. In ACCs, expression of transcription factors GATA-6 and SF-1 correlated with that of their target gene INHA. Moreover, the diminished expression of GATA-6 and SF-1 in ACCs correlated with poor outcome. We conclude that the factors driving INHA expression are reduced in ACCs with poor outcome, implicating a role for INHA as a tumor suppressor in humans.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Adenoma; Carcinoma; Inhibin; Signaling pathway; Transcription factor

Mesh:

Substances:

Year:  2013        PMID: 23866946      PMCID: PMC3777642          DOI: 10.1016/j.prp.2013.06.002

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  34 in total

1.  GATA factors differentially activate multiple gonadal promoters through conserved GATA regulatory elements.

Authors:  J J Tremblay; R S Viger
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

Review 2.  TGFbeta signaling in growth control, cancer, and heritable disorders.

Authors:  J Massagué; S W Blain; R S Lo
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.

Authors:  Sébastien Gaujoux; Stéphane Pinson; Anne-Paule Gimenez-Roqueplo; Laurence Amar; Bruno Ragazzon; Pierre Launay; Tchao Meatchi; Rossella Libé; Xavier Bertagna; Anne Audebourg; Jessica Zucman-Rossi; Frédérique Tissier; Jérôme Bertherat
Journal:  Clin Cancer Res       Date:  2010-10-26       Impact factor: 12.531

4.  Synergistic activation of the inhibin alpha-promoter by steroidogenic factor-1 and cyclic adenosine 3',5'-monophosphate.

Authors:  M Ito; Y Park; J Weck; K E Mayo; J L Jameson
Journal:  Mol Endocrinol       Date:  2000-01

Review 5.  Adrenal incidentalomas.

Authors:  Jérôme Bertherat; Helen Mosnier-Pudar; Xavier Bertagna
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

Review 6.  Adrenal incidentaloma.

Authors:  L M Brunt; J F Moley
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

7.  Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm.

Authors:  J Arola; J Liu; P Heikkilä; V Ilvesmäki; K Salmenkivi; R Voutilainen; A I Kahri
Journal:  J Endocrinol       Date:  2000-05       Impact factor: 4.286

Review 8.  Steroidogenic factor 1: an essential mediator of endocrine development.

Authors:  Keith L Parker; Douglas A Rice; Deepak S Lala; Yayoi Ikeda; Xunrong Luo; Margaret Wong; Marit Bakke; Liping Zhao; Claudia Frigeri; Neil A Hanley; Nancy Stallings; Bernard P Schimmer
Journal:  Recent Prog Horm Res       Date:  2002

9.  Differential expression of GATA-4 and GATA-6 in fetal and adult mouse and human adrenal tissue.

Authors:  Sanne Kiiveri; Jianqi Liu; Mia Westerholm-Ormio; Naoko Narita; David B Wilson; Raimo Voutilainen; Markku Heikinheimo
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

10.  Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production.

Authors:  Minna Heikkilä; Hellevi Peltoketo; Juhani Leppäluoto; Mika Ilves; Olli Vuolteenaho; Seppo Vainio
Journal:  Endocrinology       Date:  2002-11       Impact factor: 4.736

View more
  11 in total

Review 1.  Toying with fate: Redirecting the differentiation of adrenocortical progenitor cells into gonadal-like tissue.

Authors:  Theresa Röhrig; Marjut Pihlajoki; Ricarda Ziegler; Rebecca S Cochran; Anja Schrade; Maximiliaan Schillebeeckx; Robi D Mitra; Markku Heikinheimo; David B Wilson
Journal:  Mol Cell Endocrinol       Date:  2014-12-08       Impact factor: 4.102

Review 2.  Transforming growth factor beta1 and aldosterone.

Authors:  Kota Matsuki; Catherine K Hathaway; Albert S Chang; Oliver Smithies; Masao Kakoki
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-03       Impact factor: 2.894

Review 3.  GATA factors in endocrine neoplasia.

Authors:  Marjut Pihlajoki; Anniina Färkkilä; Tea Soini; Markku Heikinheimo; David B Wilson
Journal:  Mol Cell Endocrinol       Date:  2015-05-28       Impact factor: 4.102

Review 4.  The role of transforming growth factor β1 in the regulation of blood pressure.

Authors:  Kota Matsuki; Catherine K Hathaway; Marlon G Lawrence; Oliver Smithies; Masao Kakoki
Journal:  Curr Hypertens Rev       Date:  2014

5.  LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.

Authors:  Yuxiu Gao; Ning Shan; Cheng Zhao; Yunhai Wang; Fuliang Xu; Jiacun Li; Xiaoqian Yu; Lifeng Gao; Zhengjun Yi
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Adrenocortical zonation, renewal, and remodeling.

Authors:  Marjut Pihlajoki; Julia Dörner; Rebecca S Cochran; Markku Heikinheimo; David B Wilson
Journal:  Front Endocrinol (Lausanne)       Date:  2015-03-05       Impact factor: 5.555

Review 7.  Deubiquitinases and the new therapeutic opportunities offered to cancer.

Authors:  Roland Pfoh; Ira Kay Lacdao; Vivian Saridakis
Journal:  Endocr Relat Cancer       Date:  2015-02       Impact factor: 5.678

8.  Steroidogenic factor-1 hypermethylation in maternal rat blood could serve as a biomarker for intrauterine growth retardation.

Authors:  Dong-Mei Wu; Liang-Peng Ma; Gui-Li Song; Yong Long; Han-Xiao Liu; Yang Liu; Jie Ping
Journal:  Oncotarget       Date:  2017-10-10

9.  Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

Authors:  Yi Zhu; Minjie Wang; Xu Zhao; Lei Zhang; Yigao Wu; Bangqi Wang; Weilie Hu
Journal:  Oncotarget       Date:  2017-04-04

10.  A transcription factor signature predicts the survival of patients with adrenocortical carcinoma.

Authors:  Jianyu Zhao; Bo Liu; Xiaoping Li
Journal:  PeerJ       Date:  2021-12-09       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.